Galectin Therapeutics Stock Today
| GALT Stock | USD 2.00 0.02 0.99% |
Performance0 of 100
| Odds Of DistressOver 83
|
Galectin Therapeutics is selling for under 2.00 as of the 20th of December 2024; that is 0.99 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 1.9. Galectin Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 20th of November 2024 and ending today, the 20th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of September 2002 | Category Healthcare | Classification Health Care |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia. Galectin Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 62.76 M outstanding shares of which 5.86 M shares are currently shorted by private and institutional investors with about 42.37 trading days to cover. More on Galectin Therapeutics
Moving together with Galectin Stock
Moving against Galectin Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Galectin Stock Highlights
| Thematic Idea | Israel Wall Street (View all Themes) | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Israel Wall Street, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsGalectin Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Galectin Therapeutics' financial leverage. It provides some insight into what part of Galectin Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||
Galectin Therapeutics (GALT) is traded on NASDAQ Exchange in USA. It is located in 4960 Peachtree Industrial Boulevard, Norcross, GA, United States, 30071 and employs 14 people. Galectin Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 125.52 M. Galectin Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 62.76 M outstanding shares of which 5.86 M shares are currently shorted by private and institutional investors with about 42.37 trading days to cover.
Galectin Therapeutics currently holds about 15.83 M in cash with (32.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27.
Check Galectin Therapeutics Probability Of Bankruptcy
Ownership AllocationGalectin Therapeutics has a total of 62.76 Million outstanding shares. Galectin Therapeutics secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Galectin Ownership Details
Galectin Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Cutter & Co Brokerage, Inc. | 2024-09-30 | 115.5 K | |
| Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 114.7 K | |
| Sanctuary Advisors, Llc | 2024-06-30 | 100.7 K | |
| Lpl Financial Corp | 2024-09-30 | 81.9 K | |
| Susquehanna International Group, Llp | 2024-09-30 | 81.5 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 65.1 K | |
| Retirement Guys Formula Llc | 2024-09-30 | 63.8 K | |
| Marshall Wace Asset Management Ltd | 2024-09-30 | 52.3 K | |
| Horizon Asset Management Inc/ny | 2024-09-30 | 51.5 K | |
| Vanguard Group Inc | 2024-09-30 | 2.1 M | |
| Blackrock Inc | 2024-06-30 | 1.6 M |
Galectin Therapeutics Historical Income Statement
Galectin Stock Against Markets
Galectin Therapeutics Corporate Management
| CPA CPA | Treasurer CFO | Profile | |
| Khurram MD | Chief Officer | Profile | |
| Jeff Katstra | Head Development | Profile | |
| Robert Tritt | General Counsel | Profile | |
| Beth Knowles | Executive Manager | Profile |
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.